FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCognition Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CGTX
Cognition Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Cognition Therapeutics, Inc. (CGTX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCGTX
CGTX
Cognition Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CGTX
  1. Home
  2. Stocks
  3. Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc.

🇺🇸CGTX•NASDAQ

Cognition Therapeutics, Inc.

🇺🇸CGTX•NASDAQ
Market cap
$55.37M

Your view on CGTX

Mkt Cap
$55.37M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Cognition Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Lisa Ricciardi
Headquarters
2500 Westchester Avenue, Purchase, NY, US
Industry
Biotechnology
Sector
Healthcare
CEO
Lisa Ricciardi
Headquarters
2500 Westchester Avenue, Purchase, NY, US
Description

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD).

The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Cognition Therapeutics, Inc.. Starting points for Cognition Therapeutics, Inc.: EPS -$0.17, beta 1.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Cognition Therapeutics, Inc.. Trailing twelve-month EPS for Cognition Therapeutics, Inc. stands at -$0.17. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Cognition Therapeutics, Inc.. Cognition Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CGTX12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PRNAFAlterity Therapeutics LimitedHealthcareOTC$109.8M
PROKProKidney Corp.HealthcareNASDAQ$349.7M
PROTProteonomix, Inc.HealthcareOTC$791
PRQRProQR Therapeutics N.V.HealthcareNASDAQ$146.8M
PRRUFImmutep LimitedHealthcareOTC$368.0M
PRTAProthena Corporation plcHealthcareNASDAQ$422.1M
PRTCYPureTech Health plcHealthcareOTC—
PRVCFPreveCeutical Medical Inc.HealthcareOTC$10.1M
PSYBFPsyBio Therapeutics Corp.HealthcareOTC$1,275
PTCHFPureTech Health plcHealthcareOTC$410.4M
PTCTPTC Therapeutics, Inc.HealthcareNASDAQ$4.7B
PTGXProtagonist Therapeutics, Inc.HealthcareNASDAQ$7.9B
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Cognition Therapeutics, Inc., and how their positions are changing. At a $55.4M market value, institutional positions materially move Cognition Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Cognition Therapeutics, Inc. executives and directors. Shares of Cognition Therapeutics, Inc. have traded between $0.22 and $3.83 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Cognition Therapeutics, Inc.. Coverage tracks Cognition Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Cognition Therapeutics, Inc.

CGTX AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1